Skip to main content
Dr. Lal Pathlabs Limited logo

Dr. Lal Pathlabs Limited — Investor Relations & Filings

Ticker · LALPATHLAB ISIN · INE600L01024 LEI · 984500E8E9CY102B9718 BSE.NS Human health and social work activities
Open in API
Filings indexed 1,098 across all filing types
Latest filing 2019-11-08 Investor Presentation
Country IN India
Listing BSE.NS LALPATHLAB

About Dr. Lal Pathlabs Limited

https://www.lalpathlabs.com/

Dr. Lal Pathlabs Limited is a provider of diagnostic and related healthcare tests and services. The company offers a comprehensive range of clinical laboratory tests and profiles used for prediction, early detection, diagnostic screening, confirmation, and monitoring of diseases. Its service portfolio encompasses pathology, including biochemistry, hematology, clinical pathology, histopathology, and molecular diagnostics, as well as radiology services such as X-ray, ultrasound, and CT scans. The organization operates an extensive network of laboratories, patient service centers, and pick-up points, utilizing advanced automated systems and standardized processes. Key offerings include specialized wellness packages and home sample collection. The company maintains high quality standards through international and national accreditations, serving a diverse patient base and healthcare providers with a focus on accuracy and timely reporting.

Recent filings

Filing Released Lang Actions
Investor Presentation
Investor Presentation Classification · 100% confidence The document is titled as an "Investors Presentation on Unaudited Financial Results (Standalone and Consolidated) for the Quarter & Half Year ended September 30, 2019." It includes detailed financial data such as revenues, EBITDA, PAT, margins, and EPS for Q2 and half year FY20, along with operational highlights and strategic commentary. The document is clearly a presentation intended for investors and analysts, focusing on financial results and business overview. It is not a full annual report, audit report, or earnings release announcement but a detailed presentation of quarterly and half-year financial results. Therefore, the document fits the category of an Investor Presentation (IP). The document length is 15,000 characters, indicating it is a full presentation, not just an announcement or a brief summary.
2019-11-08 English
Press Release
Earnings Release Classification · 95% confidence The document is a press release dated November 8, 2019, announcing unaudited financial results for the quarter and half year ended September 30, 2019. It includes detailed financial performance highlights such as revenue growth, EBITDA, PBT, PAT, and EPS for Q2 FY20 compared to Q2 FY19. The document is titled as a press release and contains substantive financial data and analysis for a quarterly period, indicating it is a financial results announcement. It is not a full annual report, audit report, or management discussion but rather an initial announcement of quarterly financial results. Therefore, it fits the definition of an Earnings Release (ER). The document length is 6645 characters, which is sufficient to contain detailed financial highlights rather than just a brief announcement or a report publication notice. Hence, the classification is Earnings Release (ER) with high confidence. Q2 2020
2019-11-08 English
Dividend
Capital/Financing Update Classification · 95% confidence The document is a notification addressed to stock exchanges regarding the approval of unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2019. It also declares an interim dividend and provides details about the record date and payment date. The document references Regulation 30 & 33 of SEBI Listing Regulations, which govern disclosure of financial results and dividend declarations. The document length is 2132 characters, which is relatively short and primarily serves as an announcement rather than containing detailed financial statements or analysis. It includes a limited review report mention but does not contain the full financial report itself. Therefore, this document is best classified as a Capital/Financing Update (CAP) because it announces interim dividend and financial results approval without providing the full report or detailed financial data.
2019-11-08 English
Financial Result Updates
Regulatory Filings
2019-11-08 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is an invitation letter for a conference call scheduled to discuss the Q2 & H1 FY20 financial and operating performance of Dr. Lal PathLabs Ltd. It mentions the date and time of the call, the management participants, and dial-in details. The document does not contain actual financial statements or detailed financial analysis but is an announcement of the upcoming earnings conference call. According to the classification rules, such documents are classified as Call Transcript (CT) only if they contain the full transcript of the call, including Q&A. Since this is only an invitation and announcement of the call, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other categories. The document length is about 5800 characters, which is not extremely short, but the content is clearly an announcement, not the report or transcript itself.
2019-11-05 English
Board Meeting — Financial Results/Dividend
Regulatory Filings Classification · 95% confidence The document is a notice from a company to stock exchanges about an upcoming Board Meeting scheduled for November 8, 2019. The purpose of the meeting includes considering and approving unaudited financial results for the quarter and half year ended September 30, 2019, and considering a proposal for an interim dividend. The document is short (1570 characters) and serves as an announcement of a future event rather than containing actual financial results or detailed reports. It references Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, which governs disclosures related to board meetings and financial results announcements. Since this is a notice of a board meeting and not the actual financial report or dividend declaration, it fits best under Regulatory Filings (RNS), which is the fallback category for such regulatory announcements that do not fit other specific categories.
2019-10-18 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.